top of page

Treace Medical Lawsuit: Fact, Fiction or Both?

Consider these three angles following the shareholder alert over the Treace Medical Investigation last week.


1. Fact

The double-edged sword of aggressive direct to consumer advertising, and questionable billing/coding suggestions to physicians to justify the higher cost of the “lapiplasty” kit finally caught up to the company, as reported by Culper Research.


2. Fiction

With a billion dollar plus valuation, Treace Medical is too large for an acquisition/merger, yet its portfolio is also too small to fend off long-term industry competition.


Let's entertain, for a moment, the possibility of a “short with an option”: Traditionally, you buy stock first and sell it later. With a "short with an option," you sell borrowed stock first and buy it back later, for cheaper. It may seem complicated, but it's an easy way to hedge against long positions by “buying” for less, in anticipation that market uncertainty and fear in the future will reduce the price down further – yielding a large return on investment long-term.


In other words, capital and growth can be generated without any of the associated traditional costs and loses. Click here for more on “shorting.”


3. Both

Success has many enemies, and often welcomes unwanted attention. Perhaps the investigation by Holzer & Holzer, LLC, an ISS top-rated securities litigation law firm, is yet another cautionary example for other companies currently focusing in on and harnessing direct-to-consumer advertising and social media to inflate their annual ROIs, simultaneously creating opportunity for market investors.

3 views0 comments

Recent Posts

See All

BioAventis has agreed to sell its wound business to LifeNet Health, which includes skin substitutes TheraSkin and TheraGenesis. The transaction includes a total cash consideration of $85 million. Indu

Dr. Ned Amendola MD, FAAOS, FRCS(C) from Duke University was named second vice president of the American Academy of Orthopedic Surgeons (AAOS) and will ascend to president in 2025-2026. Fellowship tra

As speculated in February 2023 FIX, Enovis announced early this week that it has consummated a deal for Novastep with the MIS bunion system being the prize along with access to a robust OUS sales chan

FIX Masthead 2000x318 v2.jpg
bottom of page